Intramedullary Osteosarcoma Treatment Market Trends

Growth Drivers

• Growing Awareness Regarding the Disease - As awareness grows, so does the need for more sophisticated treatment choices, which drives up funding for the study and creation of novel treatments and technological solutions for intramedullary osteosarcoma. For instance, the Bone Cancer Awareness Initiative, a 100-day program aims to reach all general practitioners (GP practices), medical students, radiology departments, muscular skeletal physiotherapists, and pharmacies in the UK. It culminates in Bone Cancer Awareness Week (5-11 October). This initiative equips them—for the first time—with the information and specific instruments needed to recognize a possible case of primary bone cancer and to confirm or rule out a diagnosis. Therefore, public health awareness campaigns are also escalating the growth of the market.
• Growing Initiatives for R&D Activities by Governments Worldwide – The market expansion can be attributed to the increased government funding for R&D activities for various diseases and treatments. Also, governments in various nations are highly investing in the healthcare sector which is also accelerating the market growth. For instance, in 2021, 73% of healthcare spending in various nations was funded by public sources on average. In countries like Norway, Sweden, and Denmark where government financing schemes are the primary source of funding, government transfers account for at least 85% of healthcare spending. The majority of public funding in other nations, like Slovenia or Germany, relates to social insurance contributions that businesses and employees are required to provide.Therefore, this factor is expected to drive the growth of the intramedullary osteosarcoma treatment market.
• Surge in Technological Advancements – The advent of advanced imaging methods like MRIs, CT scans, and PET scans as a result of technological breakthroughs has made it possible to identify intramedullary osteosarcoma earlier and with more accuracy. Additionally, advancements in robotic surgery and computer-assisted navigation have improved the efficacy and precision of tumor excision while reducing harm to adjacent healthy tissue. As per a report, between 2012 and 2018, the proportion of surgical procedures in the US carried out using robotic technology rose from 0% to 19%. Furthermore, the application of personalized medicine techniques in the management of intramedullary osteosarcoma has been made easier by technological developments.

Challenges

• Toxicity of Chemotherapy – Treatment for intramedullary osteosarcoma with chemotherapy regimens has the potential to cause serious adverse effects, such as myelosuppression, gastrointestinal distress, neuropathy, and cardiotoxicity. Healthcare practitioners face a clinical challenge in managing these side effects while maintaining treatment efficacy. Therefore, this factor may hinder the growth of the market throughout the projected period.
• High Costs of Treatment may Hamper the Market Growth
• Surgical Resection of Intramedullary Osteosarcoma can be Technically Challenging Which May Impede the Growth of the Market